Adomeglivant

Drug Profile

Adomeglivant

Alternative Names: LY-2409021

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antihyperglycaemics; Benzamides; Propionic acids; Small molecules
  • Mechanism of Action Glucagon receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 01 Oct 2015 Eli Lilly and Sofie Haedersdal University hospital initiate a clinical trial for Type-2 diabetes mellitus in Denmark by invitation only (NCT02669524)
  • 01 May 2015 Eli Lilly completes a phase I trial in Healthy volunteers in USA (NCT02385084)
  • 16 Mar 2015 Eli Lilly plans a phase I trial in Healthy volunteers in USA (NCT02385084)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top